Profluent
Private Company
Total funding raised: $150M
Overview
Profluent is an AI-first protein design company pioneering the use of large language models and other foundation AI models to generate and optimize novel protein sequences. The company integrates its computational platform with an in-house wet lab to experimentally validate designs, creating a closed-loop system for developing proteins with desired functions. Its initial proof-of-concept, OpenCRISPR, demonstrates the platform's ability to design complex gene-editing systems, positioning Profluent at the intersection of generative AI and synthetic biology. The company operates as a platform technology provider, partnering with other entities to apply its AI to diverse challenges in medicine and beyond.
Technology Platform
Integrated AI platform using large language models and other foundation models to design and optimize novel, functional protein sequences. The platform combines computational design with in-house wet lab validation in a closed-loop system.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Profluent competes in the rapidly emerging field of AI-driven protein design. Key competitors include other specialized startups (e.g., EvolutionaryScale, Arc Institute spin-offs) and large tech companies with AI biology initiatives, such as Google's DeepMind/Isomorphic Labs. Traditional protein engineering companies and large biopharma with internal AI groups also represent competitive forces.